Komori
Zeria Pharmaceutical (4559) · RiskDropped

Accounting Estimate Uncertainty Related to the Impact of COVID-19

First written in FY2023-Q1. 2 of 4 entries say "Restated". Latest entry: FY2024.

4entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2023-Q1 – FY20242022: 220222023: 120232024: 12024
Same theme, other companies
Assumptions Used in Accounting Estimates for COVID-19A theme 59 companies write about · 27 as a headwind · 0 as a tailwind

8 other companies' latest entry also says "Dropped".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 59 companies compared. The sentences above are computed from all 59.
Full recordFilings, disclosures and news, newest first
  1. FY2024DroppedAnnual report
    No separate disclosure for the fiscal year in question could be identified regarding the uncertainty in accounting estimates related to the impact of COVID-19 that had been disclosed previously.
  2. FY2023-Q3RestatedAnnual report

    「The Group has made accounting estimates on the assumption that the impact of COVID-19 will continue for a certain period, and there has been no significant change in the assumptions underlying those estimates from the previous consolidated fiscal year. However, if circumstances change in the future and the resulting judgments are revised, the changes may have a material impact on future consolidated financial statements.」

    The Company continues to disclose the accounting estimates based on the assumption that the impact of COVID-19 will continue for a certain period and the possibility that future changes in circumstances may affect the financial statements.
  3. FY2023-Q2RestatedAnnual report

    「The Group has made accounting estimates on the assumption that the impact of COVID-19 will continue for a certain period, and there has been no significant change in the assumptions underlying those estimates from the previous consolidated fiscal year. However, if circumstances change in the future and the resulting judgments are revised, the changes may have a material impact on future consolidated financial statements.」

    The Company continues to disclose the accounting estimates based on the assumption that the impact of COVID-19 will continue for a certain period and the possibility that future changes in circumstances may affect the financial statements.
  4. FY2023-Q1First statedAnnual report

    「The Group has made accounting estimates on the assumption that the impact of COVID-19 will continue for a certain period, and there has been no significant change in the assumptions underlying those estimates from the previous consolidated fiscal year. However, if circumstances change in the future and the resulting judgments are revised, the changes may have a material impact on future consolidated financial statements.」

    The Group has made accounting estimates based on the assumption that the impact of COVID-19 will continue for a certain period, and for the first time has described the possibility that future changes in circumstances may materially affect the future consolidated financial statements as a separate accounting risk.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Zeria Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.